August 2015

 

In this Supplement

The Evolution of SFA Care: The DCB Paradigm Shift

An in-depth look at how the science and clinical use of the first FDA-approved drug-coated balloon, LUTONIX® 035, continues to advance the treatment of PAD.

Issue

Supplement

Supplement

Supplement

Download a PDF of this supplement

Drug-Coated Balloons: The Future Ahead

Experts weigh in on the ongoing trial data supporting the use of drug-coated balloons.

By J.A. Mustapha, MD; Patrick J. Geraghty, MD; Carlos Mena, MD; and Scott Trerotola, MD

Treatment Algorithms: This Is How I Use a DCB

An expert panel discusses the current role, data, and techniques for the use of drug-coated balloons in tackling PAD.

By J.A. Mustapha, MD; Chad R. Laurich, MD; Lawrence A. Garcia, MD; Patrick J. Geraghty, MD; and Prakash Krishnan, MD

Safety of Drug-Coated Balloons: Insight from Preclinical Studies

Understanding the advantages and disadvantages that can result from different balloon technologies on the market.

By Kazuyuki Yahagi, MD; Frank D. Kolodgie, PhD; and Renu Virmani, MD

The Economic Impact of Drug-Coated Balloons in the SFA

From a financial standpoint, DCBs have become the most attractive endovascular option for treating atherosclerosis in the superficial femoral artery.

By Mark W. Burket, MD

The Role of SFA Stenting in the DCB Era

How will drug-coated balloons change the role of stenting in the SFA?

By Constantino S. Peña, MD
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.